tradingkey.logo
๎™

Cytek Biosciences Inc

CTKB
5.100USD
+0.030+0.59%
์ข…๊ฐ€ย 12/26, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
652.11M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Cytek Biosciences Inc ํšŒ์‚ฌ

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Cytek Biosciences Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ CTKB
ํšŒ์‚ฌ ์ด๋ฆ„Cytek Biosciences Inc
์ƒ์žฅ์ผJul 23, 2021
CEOJiang (Wenbin)
์ง์› ์ˆ˜648
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒJul 23
์ฃผ์†Œ47215 Lakeview Boulevard
๋„์‹œFREMONT
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ94538
์ „ํ™”18779229835
์›น์‚ฌ์ดํŠธhttps://cytekbio.com
์ข…๋ชฉ ์ฝ”๋“œ CTKB
์ƒ์žฅ์ผJul 23, 2021
CEOJiang (Wenbin)

Cytek Biosciences Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
12.36K
+21.43%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
์ง€์—ญ๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Nov 16
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Nov 16
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
๊ธฐํƒ€
67.30%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
๊ธฐํƒ€
67.30%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
28.05%
Investment Advisor/Hedge Fund
22.30%
Hedge Fund
9.95%
Individual Investor
9.31%
Research Firm
1.43%
Pension Fund
1.21%
Bank and Trust
0.17%
Family Office
0.12%
Venture Capital
0.06%
๊ธฐํƒ€
27.39%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
319
80.93M
70.83%
-2.20K
2025Q3
325
80.93M
70.98%
+589.69K
2025Q2
322
80.49M
71.67%
+1.88M
2025Q1
319
78.68M
72.45%
-13.77M
2024Q4
315
78.50M
69.87%
+2.46M
2024Q3
291
75.89M
70.06%
-1.14M
2024Q2
277
76.97M
68.86%
-4.44M
2024Q1
273
87.08M
76.11%
-12.82M
2023Q4
268
85.37M
77.21%
+1.48M
2023Q3
258
83.84M
73.24%
+597.32K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Millennium Management LLC
924.77K
0.73%
+429.33K
+86.66%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
Invesco S&P SmallCap Health Care ETF
0.26%
Royce Quant Small-Cap Quality Value ETF
0.22%
iShares S&P Small-Cap 600 Value ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
State Street SPDR S&P 600 Small Cap Value ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Principal U.S. Small-Cap ETF
0.05%
WisdomTree US SmallCap Fund
0.04%
๋” ๋ณด๊ธฐ
Invesco S&P SmallCap Health Care ETF
๋น„์œจ0.26%
Royce Quant Small-Cap Quality Value ETF
๋น„์œจ0.22%
iShares S&P Small-Cap 600 Value ETF
๋น„์œจ0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
๋น„์œจ0.07%
State Street SPDR S&P 600 Small Cap Value ETF
๋น„์œจ0.06%
Avantis US Small Cap Equity ETF
๋น„์œจ0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
๋น„์œจ0.05%
Fidelity Enhanced Small Cap ETF
๋น„์œจ0.05%
Principal U.S. Small-Cap ETF
๋น„์œจ0.05%
WisdomTree US SmallCap Fund
๋น„์œจ0.04%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Cytek Biosciences Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Cytek Biosciences Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
BlackRock Institutional Trust Company, N.A.๋Š” 15.38M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 12.09%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Topline Capital Management, LLC๋Š” 5.23M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 4.11%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
The Vanguard Group, Inc.๋Š” 7.74M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 6.08%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
HHLR Advisors, Ltd.๋Š” 6.66M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 5.23%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Yan (Ming)๋Š” 6.06M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 4.76%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Cytek Biosciences Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Cytek Biosciences Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
BlackRock Institutional Trust Company, N.A.
Topline Capital Management, LLC
The Vanguard Group, Inc.์ž…๋‹ˆ๋‹ค.

Cytek Biosciences Inc(CTKB)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q4 ๊ธฐ์ค€์œผ๋กœ, Cytek Biosciences Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 319๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 80.93M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 70.83%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q3 ๋Œ€๋น„ -0.14% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Cytek Biosciences Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
FY2025Q2 ๊ธฐ์ค€, Cytek Biosciences Inc์˜ Biotechnology, pharmaceutical, distributor and CRO ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 23.85M๋กœ ์ „์ฒด ๋งค์ถœ์˜ 52.30%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™